Drug Profile
SAR 21609
Alternative Names: SAR21609Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Coley Pharmaceutical Group; sanofi-aventis
- Developer Sanofi
- Class Antiasthmatics; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Respiratory tract infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in France
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-tract-infections in France
- 11 Feb 2009 Phase-I clinical trials in Asthma in France (unspecified route)